Penn and CHOP will test gene therapy for rare diseases with a new FDA trial protocol

Earlier this year, researchers at CHOP and Penn created a first-of-its-kind drug customized to a unique genetic mutation to save an infant named Baby KJ from dying of a rare liver disorder. KJ Muldoon ...
STATOpinion

Celebrating a new, faster path to gene-editing medicines on demand

The FDA’s Marty Makary and Vinay Prasad have laid out a path for CRISPR treatments on demand. An expert weighs in on what it ...
NPR

How CRISPR can edit entire microbial populations in our gut

Part 4 of the TED Radio Hour episode Augmenting Humans. Jennifer Doudna's gene-editing technology CRISPR can now manipulate populations of microbes. This new field, called precision microbiome editing ...

CRISPR therapy setback: Intellia pauses Phase 3 ATTR trials as patient develops serious liver reaction to nex-z

Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as the company investigates and works with regulators on its CRISPR-based ...

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Conference call today at 8:30 a.m. ETCAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on ...
The Motley Fool

Where Will CRISPR Therapeutics Be in 5 Years?

CRISPR Therapeutics now has an approved product in its portfolio in Casgevy. The treatment has the potential to be a game changer for the company's business. Even with more treatments in its portfolio ...